Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Preleukemia

Myelodysplastic Syndromes

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Azacitidine

Decitabine

Homoharringtonine

Antimetabolites

Enzyme Inhibitors

one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)

one course of Decitabine (5-aza-deoxycytidine,Dacogen)

cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.

CHG regimen

Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.

5-aza-deoxycytidine

Xiao Li, Doctor

Lingyun Wu, Doctor

Xiao Li

Chunkang Chang, Doctor

The purpose of this study is to compare the efficacy of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) to decitabine in the treatment of higher-risk myelodysplastic syndromes(MDS).

Patients with higher-risk myelodysplastic syndrome (MDS) have a survival rate of 0.4 to 1.2 years as well as a high risk of their disease progressing to acute myeloid leukemia (AML). The only treatment with a curative potential is allogeneic stem cell transplantation. However, in the majority of patients, this treatment is not applicable, mainly due to the age of the recipients and comorbid conditions. Low-dose chemotherapy CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming)has been used to treat higher-risk MDS in China and achieve high response rate. Hypomethylating agents 5-aza-2'-deoxycytidine (decitabine) is nucleoside analogs that covalently bind to the DNA methyltransferases, irreversibly inhibiting their function, leading to the progressive loss of methylation and reversal of gene silencing. The purpose of this study is to compare the efficacy and safety of CHG regimen to Decitabine in higher-risk MDS.

Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

Doctor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS	NCT01417767	Myelodysplastic...	CHG regimen 5-aza-deoxycyti...	16 Years - 80 Years	Shanghai 6th People's Hospital
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS	NCT01417767	Myelodysplastic...	CHG regimen 5-aza-deoxycyti...	16 Years - 80 Years	Shanghai 6th People's Hospital
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS	NCT01417767	Myelodysplastic...	CHG regimen 5-aza-deoxycyti...	16 Years - 80 Years	Shanghai 6th People's Hospital

Spots Global Cancer Trial Database for chg regimen

Every month we try and update this database with for chg regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for chg regimen

Every month we try and update this database with for chg regimen cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for chg regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.